Evidence-based value and access strategies

Case Study: Indication Prioritization


Return to Clinical & Market Access Intelligence


Compass conducted an assessment of product concepts in dermatology to guide a pharma company in prioritizing their portfolio

Situation:
A pharma client requested evidence-based priorities and target product profile characteristics to guide the priorities for their dermatology portfolio

Key Objective:
Provide a solid rationale for prioritization of dermatology product concepts in development through an assessment of clinical and economic attributes, price ranges and access

Methodology:
In-depth interviews with ten US commercial and Medicare payers

Results:

  • Identified efficacy / safety endpoints and additional economic data that would drive value to payers
  • Comprehensive assessment of each product concept by payers
  • Defined a price range for each product concept and expected formulary access
  • Assessed payers’ future priorities in managing and funding treatments for patients in this therapeutic category and identified how this will affect access to the products tested
  • Identified products to prioritize based on payer assessment
Sample Deliverable
Assessment of efficacy, safety and cost attributes identified efficacy attributes as the key value drivers for payers in the category
CS_Indication